Amring Pharms patents expiration
1. Lysteda patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9060939 | AMRING PHARMS | Tranexamic acid formulations |
Mar, 2025
(1 year, 5 months from now) | |
| US7947739 | AMRING PHARMS | Tranexamic acid formulations |
Mar, 2025
(1 year, 5 months from now) | |
| US8022106 | AMRING PHARMS | Tranexamic acid formulations |
Mar, 2025
(1 year, 5 months from now) | |
| US8273795 | AMRING PHARMS | Tranexamic acid formulations |
Mar, 2025
(1 year, 5 months from now) | |
| US8487005 | AMRING PHARMS | Tranexamic acid formulations |
Mar, 2025
(1 year, 5 months from now) | |
| US8791160 | AMRING PHARMS | Tranexamic acid formulations |
Mar, 2025
(1 year, 5 months from now) | |
| US8957113 | AMRING PHARMS | Tranexamic acid formulations |
Mar, 2025
(1 year, 5 months from now) | |
| US8809394 | AMRING PHARMS | Tranexamic acid formulations |
Mar, 2025
(1 year, 5 months from now) | |
Drugs and Companies using TRANEXAMIC ACID ingredient
Market Authorisation Date: 13 November, 2009
Treatment: Treatment of cyclic heavy menstrual bleeding
Dosage: TABLET;ORAL
How can I launch a generic of LYSTEDA before it's drug patent expiration?
More Information on Dosage
LYSTEDA family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic